个人简介
Dr. Richard E. Chaisson is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in epidemiology and in international health, both in the Johns Hopkins Bloomberg School of Public Health. His area of clinical expertise is infectious diseases, particularly HIV/AIDS.
Dr. Chaisson serves as the director of the Johns Hopkins University Center for Tuberculosis Research, the director and principal investigator of the Johns Hopkins Center for AIDS Research and the director of the Consortium to Respond Effectively to the AIDS/TB Epidemic.
He received his B.S. and M.D. degrees from the University of Massachusetts. He was an intern, resident and fellow at the University of California, San Francisco, where he was also an assistant professor of medicine.
From 1988 to 1998 he was director of the Johns Hopkins AIDS Service, and he co-founded the Johns Hopkins HIV Clinic cohort, an observational study that has been the source of more than 130 scientific publications on the outcomes of HIV disease and its treatment.
Dr. Chaisson has been recognized with several honors, including the Champions of TB Control Award from the U.S. Agency for International Development (USAID) in 2014.
MD, Univ of Massachusetts Medical School-Nursing (1982)
研究领域
Dr. Chaisson’s research focuses on tuberculosis and HIV infection, including global control, prevention, clinical trials and public health interventions. He leads research projects in South Africa, Malawi, Brazil and India, and serves as chair of the Tuberculosis Transformative Science Group of the AIDS Clinical Trials Group.
He serves as the principal investigator of numerous research grants and of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE).
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Getahun H, Chaisson RE, Raviglione M. "Latent Mycobacterium tuberculosis Infection." N Engl J Med. 2015 Sep 17;373(12):1179-80. doi: 10.1056/NEJMc1508223. No abstract available.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. "Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid." JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158.
Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, Hayes RJ, Chaisson RE, Grant AD; Thibela TB Study Team. "A trial of mass isoniazid preventive therapy for tuberculosis control." N Engl J Med. 2014 Jan 23;370(4):301-10. doi: 10.1056/NEJMoa1214289.
Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. "Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial." Lancet Infect Dis. 2013 Oct;13(10):852-8. doi: 10.1016/S1473-3099(13)70187-7. Epub 2013 Aug 16.
Dowdy DW, Golub JE, Chaisson RE, Saraceni V. "Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics." Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9557-62. doi: 10.1073/pnas.1203517109. Epub 2012 May 29.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. "Three months of rifapentine and isoniazid for latent tuberculosis infection." N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.
Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, McIntyre JA, Gray GE, Chaisson RE. "New regimens to prevent tuberculosis in adults with HIV infection." N Engl J Med. 2011 Jul 7;365(1):11-20. doi: 10.1056/NEJMoa1005136.